Câncer de estômago

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: gastric cancer [internet publication].Texto completo

Lordick F, Carneiro F, Cascinu S, et al. Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022 Oct;33(10):1005-20.Texto completo  Resumo

1. Laurén P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31-49. Resumo

2. Kajitani T. The general rules for the gastric cancer study in surgery and pathology. Part 1. Clinical classification. Jpn J Surg. 1981 Mar;11(2):127-39. Resumo

3. Wanebo HJ, Kennedy BJ, Chmiel J, et al. Cancer of the stomach. A patient care study by the American College of Surgeons. Ann Surg. 1993 Nov;218(5):583-92. Resumo

4. World Health Organization. Global Cancer Observatory: cancer fact sheets, stomach cancer. Feb 2024 [internet publication].Texto completo

5. American Cancer Society. Annual cancer facts & figures archives. 2025 [internet publication].Texto completo

6. Sundar R, Nakayama I, Markar SR, et al. Gastric cancer. Lancet. 2025 Jun 7;405(10494):2087-102. Resumo

7. National Cancer Audit Collaborating Centre. ​National Oesophago-Gastric Cancer Audit state of the nation report september 2025. Sep 2025 [internet publication].Texto completo

8. Pabla BS, Shah SC, Corral JE, et al. Increased incidence and mortality of gastric cancer in immigrant populations from high to low regions of incidence: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2020 Feb;18(2):347-59.e5.Texto completo  Resumo

9. Laszkowska M, Zhang X, Kuliszewski MG, et al. Heightened risk for gastric cancer among immigrant populations in New York state from high-incidence countries. Clin Gastroenterol Hepatol. 2023 Sep;21(10):2673-5.e3.Texto completo  Resumo

10. Mülder DT, van de Schootbrugge-Vandermeer HJ, O'Mahony JF, et al. Gastric cancer risk among immigrants and socioeconomic groups in the Netherlands. Cancer Epidemiol Biomarkers Prev. 2025 Jan 9;34(1):85-92.Texto completo  Resumo

11. Shah SC, Wang AY, Wallace MB, et al. AGA clinical practice update on screening and surveillance in individuals at increased risk for gastric cancer in the United States: expert review. Gastroenterology. 2025 Feb;168(2):405-16.e1.Texto completo  Resumo

12. Turati F, Tramacere I, La Vecchia C, et al. A meta-analysis of body mass index and esophageal and gastric cardia adenocarcinoma. Ann Oncol. 2013 Mar;24(3):609-17.Texto completo  Resumo

13. Ben-Aharon I, van Laarhoven HWM, Fontana E, et al. Early-onset cancer in the gastrointestinal tract Is on the rise-evidence and implications. Cancer Discov. 2023 Mar 1;13(3):538-51. Resumo

14. Jayakrishnan T, Ng K. Early-onset gastrointestinal cancers: a review. JAMA. 2025 Oct 21;334(15):1373-85. Resumo

15. Wu B, Yang D, Yang S, et al. Dietary salt intake and gastric cancer risk: a systematic review and meta-analysis. Front Nutr. 2021 Dec 8;8:801228.Texto completo  Resumo

16. Shibata A, Parsonnet J, Longacre TA, et al. CagA status of Helicobacter pylori infection and p53 mutations in gastric adenocarcinoma. Carcinogenesis. 2002 Mar;23(3):419-24. Resumo

17. Eslick GD, Lim LL, Byles JE, et al. Association of Helicobacter pylori infection with gastric carcinoma: a meta-analysis. Am J Gastroenterol. 1999 Sep;94(9):2373-9. Resumo

18. Lochhead P, El-Omar EM. Helicobacter pylori infection and gastric cancer. Best Pract Res Clin Gastroenterol. 2007;21(2):281-97. Resumo

19. Nam SY, Park BJ, Nam JH, et al. Effect of Helicobacter pylori eradication and high-density lipoprotein on the risk of de novo gastric cancer development. Gastrointest Endosc. 2019 Sep;90(3):448-56.e1. Resumo

20. Choi IJ, Kim CG, Lee JY, et al. Family history of gastric cancer and helicobacter pylori treatment. N Engl J Med. 2020 Jan 30;382(5):427-36.Texto completo  Resumo

21. Zabaleta J. Multifactorial etiology of gastric cancer. Methods Mol Biol. 2012;863:411-35.Texto completo  Resumo

22. Wroblewski LE, Peek RM Jr, Wilson KT. Helicobacter pylori and gastric cancer: factors that modulate disease risk. Clin Microbiol Rev. 2010 Oct;23(4):713-39.Texto completo  Resumo

23. Lamb A, Chen LF. Role of the Helicobacter pylori-induced inflammatory response in the development of gastric cancer. J Cell Biochem. 2013 Mar;114(3):491-7. Resumo

24. Hsing AW, Hansson LE, McLaughlin JK, et al. Pernicious anemia and subsequent cancer: a population-based cohort study. Cancer. 1993 Feb 1;71(3):745-50. Resumo

25. You WC, Zhang L, Yang CS, et al. Nitrite, N-nitroso compounds, and other analytes in physiological fluids in relation to precancerous gastric lesions. Cancer Epidemiol Biomarkers Prev. 1996 Jan;5(1):47-52. Resumo

26. Zheng L, Wang L, Ajani J, et al. Molecular basis of gastric cancer development and progression. Gastric Cancer. 2004;7(2):61-77. Resumo

27. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014 Sep 11;513(7517):202-9.Texto completo  Resumo

28. D'Elia L, Galletti F, Strazzullo P. Dietary salt intake and risk of gastric cancer. Cancer Treat Res. 2014;159:83-95. Resumo

29. Wu X, Chen L, Cheng J, et al. Effect of dietary salt intake on risk of gastric cancer: a systematic review and meta-analysis of case-control studies. Nutrients. 2022 Oct 12;14(20):4260.Texto completo  Resumo

30. Morais S, Costa A, Albuquerque G, et al. Salt intake and gastric cancer: a pooled analysis within the Stomach cancer Pooling (StoP) Project. Cancer Causes Control. 2022 May;33(5):779-91.Texto completo  Resumo

31. Tredaniel J, Boffetta A, Buiatti E, et al. Tobacco smoking and gastric cancer: review and meta-analysis. Int J Cancer. 1997 Aug 7;72(4):565-73. Resumo

32. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: genetic/familial high-risk assessment: colorectal, endometrial, and gastric [internet publication].Texto completo

33. Fitzgerald RC, Caldos C. Clinical implications of E-cadherin associated hereditary diffuse gastric cancer. Gut. 2004 Jun;53(6):775-8. Resumo

34. Brusselaers N, Lagergren J. Maintenance use of non-steroidal anti-inflammatory drugs and risk of gastrointestinal cancer in a nationwide population-based cohort study in Sweden. BMJ Open. 2018 Jul 7;8(7):e021869.Texto completo  Resumo

35. Ford AC, Yuan Y, Forman D, et al. Helicobacter pylori eradication for the prevention of gastric neoplasia. Cochrane Database Syst Rev. 2020 Jul 6;(7):CD005583.Texto completo  Resumo

36. Bosetti C, Santucci C, Gallus S, et al. Aspirin and the risk of colorectal and other digestive tract cancers: an updated meta-analysis through 2019. Ann Oncol. 2020 May;31(5):558-68.Texto completo  Resumo

37. Ford AC, Yuan Y, Park JY, et al. Eradication therapy to prevent gastric cancer in Helicobacterpylori-positive individuals: systematic review and meta-analysis of randomized controlled trials and observational studies. Gastroenterology. 2025 Aug;169(2):261-76.Texto completo  Resumo

38. Shami JJP, Zhao J, Pathadka S, et al. Safety and effectiveness of low-dose aspirin for the prevention of gastrointestinal cancer in adults without atherosclerotic cardiovascular disease: a population-based cohort study. BMJ Open. 2022 Feb 4;12(2):e050510.Texto completo  Resumo

39. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: gastric cancer [internet publication].Texto completo

40. Lordick F, Carneiro F, Cascinu S, et al. Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022 Oct;33(10):1005-20.Texto completo  Resumo

41. Seko-Nitta A, Nagatani Y, Murakami Y, et al. 18F-fluorodeoxyglucose uptake in advanced gastric cancer correlates with histopathological subtypes and volume of tumor stroma. Eur J Radiol. 2021 Dec;145:110048. Resumo

42. Kim HW, Won KS, Song BI, et al. Correlation of primary tumor FDG uptake with histopathologic features of advanced gastric cancer. Nucl Med Mol Imaging. 2015 Jun;49(2):135-42.Texto completo  Resumo

43. Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol. 2006 Jan 21;12(3):354-62. Resumo

44. Tracey JP, Traube M. Difficulties in the diagnosis of pseudoachalasia. Am J Gastroenterol. 1994 Nov;89(11):2014-8. Resumo

45. Amin MB, Greene FL, Edge SB, et al. AJCC (American Joint Committee on Cancer) cancer staging manual. 8th ed. New York, NY: Springer; 2017:xvii;1024.

46. Blair VR, McLeod M, Carneiro F, et al. Hereditary diffuse gastric cancer: updated clinical practice guidelines. Lancet Oncol. 2020 Aug;21(8):e386-97. Resumo

47. Bozzetti F, Marubini E, Bonfanti G, et al. Subtotal versus total gastrectomy for gastric cancer: five-year survival rates in a multicenter randomized Italian trial. Italian Gastrointestinal Tumor Study Group. Ann Surg. 1999 Aug;230(2):170-8. Resumo

48. Gouzi JL, Huguier M, Fagniez PL, et al. Total versus subtotal gastrectomy for adenocarcinoma of the gastric antrum. A French prospective controlled study. Ann Surg. 1989 Feb;209(2):162-6. Resumo

49. ASGE standards of practice committee, Forbes N, Elhanafi SE, et al. American Society for Gastrointestinal Endoscopy guideline on endoscopic submucosal dissection for the management of early esophageal and gastric cancers: summary and recommendations. Gastrointest Endosc. 2023 Sep;98(3):271-84. Resumo

50. Bennett C, Wang Y, Pan T. Endoscopic mucosal resection for early gastric cancer. Cochrane Database Syst Rev. 2009 Oct 7;(4):CD004276. Resumo

51. Takekoshi T, Baba Y, Ota H, et al. Endoscopic resection of early gastric carcinoma; results of a retrospective analysis of 308 cases. Endoscopy. 1994 May;26(4):352-8. Resumo

52. Soetikno R, Kaltenbach T, Yeh R, et al. Endoscopic mucosal resection for early cancers of the upper gastrointestinal tract. J Clin Oncol. 2005 Jul 10;23(20):4490-8. Resumo

53. Cushieri A, Fayers P, Fielding J, et al. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group. Lancet. 1996 Apr 13;347(9007):995-9. Resumo

54. Songun I, Putter H, Kranenbarg EM, et al. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010 May;11(5):439-49. Resumo

55. Sasako M, Sano T, Yamamoto S, et al; Japan Clinical Oncology Group. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med. 2008 Jul 31;359(5):453-62.Texto completo  Resumo

56. Ohtani H, Tamamori Y, Noguchi K, et al. A meta-analysis of randomized controlled trials that compared laparoscopy-assisted and open distal gastrectomy for early gastric cancer. J Gastrointest Surg. 2010 Jun;14(6):958-64. Resumo

57. Kim W, Kim HH, Han SU, et al; Korean Laparo-endoscopic Gastrointestinal Surgery Study (KLASS) Group. Decreased morbidity of laparoscopic distal gastrectomy compared with open distal gastrectomy for stage I gastric cancer: short-term outcomes from a multicenter randomized controlled trial (KLASS-01). Ann Surg. 2016 Jan;263(1):28-35. Resumo

58. Kim HH, Han SU, Kim MC, et al. Effect of laparoscopic distal gastrectomy vs open distal gastrectomy on long-term survival among patients with stage I gastric cancer: the KLASS-01 randomized clinical trial. JAMA Oncol. 2019 Apr 1;5(4):506-13.Texto completo  Resumo

59. Best LM, Mughal M, Gurusamy KS. Laparoscopic versus open gastrectomy for gastric cancer. Cochrane Database Syst Rev. 2016 Mar 31;(3):CD011389.Texto completo  Resumo

60. Dikken JL, Jansen EP, Cats A, et al. Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer. J Clin Oncol. 2010 May 10;28(14):2430-6.Texto completo  Resumo

61. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001 Sep 6;345(10):725-30.Texto completo  Resumo

62. Smalley SR, Benedetti JK, Haller DG, et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol. 2012 Jul 1;30(19):2327-33. Resumo

63. Park SH, Lim DH, Sohn TS, et al; ARTIST 2 investigators. A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial. Ann Oncol. 2021 Mar;32(3):368-74.Texto completo  Resumo

64. Moertel CG, Childs DS, Reitemeier RJ, et al. Combined 5-fluorouracil and supervoltage radiation therapy for locally advanced and metastatic gastric carcinoma. Lancet. 1969 Oct 25;2(7626):865-7. Resumo

65. Le Chevalier T, Smith FP, Harter WK, et al. Chemotherapy and combined modality therapy for locally advanced and metastatic gastric carcinoma. Semin Oncol. 1985 Mar;12(1):46-53. Resumo

66. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006 Jul 6;355(1):11-20.Texto completo  Resumo

67. Sun P, Xiang JB, Chen ZY. Meta-analysis of adjuvant chemotherapy after radical surgery for advanced gastric cancer. Br J Surg. 2009 Jan;96(1):26-33. Resumo

68. Janjigian YY, Al-Batran SE, Wainberg ZA, et al. Perioperative durvalumab in gastric and gastroesophageal junction cancer. N Engl J Med. 2025 Jul 17;393(3):217-30. Resumo

69. ClinicalTrials.gov. 5-FU, leucovorin, oxaliplatin and docetaxel (FLOT) versus epirubicin, cisplatin and 5-FU (ECF) in patients with locally advanced, resectable gastric cancer. NCT01216644. Jun 2019 [internet publication].Texto completo

70. Glimelius B, Ekström K, Hoffman K, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol. 1997 Feb;8(2):163-8. Resumo

71. Wagner AD, Syn NL, Moehler M, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2017 Aug 29;(8):CD004064.Texto completo  Resumo

72. Pyrhönen S, Kuitunen T. Nyandoto P, et al. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer. 1995 Mar;71(3):587-91. Resumo

73. Bang YJ, Van CE, Feyereislova A, et al; ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010 Aug 28;376(9742):687-97. Resumo

74. ClinicalTrials.gov. Efficacy study of nivolumab plus ipilimumab or nivolumab plus chemotherapy against chemotherapy in stomach cancer or stomach/esophagus junction cancer (CheckMate649). NCT02872116. Jun 2021 [internet publication].Texto completo

75. Kelly RJ, Ajani JA, Kuzdzal J, et al; CheckMate 577 Investigators. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med. 2021 Apr 1;384(13):1191-203.Texto completo  Resumo

76. Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021 Jul 3;398(10294):27-40.Texto completo  Resumo

77. Kang YK, Chen LT, Ryu MH, et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022 Feb;23(2):234-47. Resumo

78. Janjigian YY, Ajani JA, Moehler M, et al. First-line nivolumab plus chemotherapy for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 3-year follow-up of the phase III checkMate 649 trial. J Clin Oncol. 2024 Jun 10;42(17):2012-20.Texto completo  Resumo

79. Shah MA, Kennedy EB, Alarcon-Rozas AE, et al. Immunotherapy and targeted therapy for advanced gastroesophageal cancer: ASCO guideline. J Clin Oncol. 2023 Mar 1;41(7):1470-91.Texto completo  Resumo

80. National Institute for Health and Care Excellence. Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma. Aug 2024 [internet publication].Texto completo

81. Shah MA, Shitara K, Ajani JA, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023 Aug;29(8):2133-41.Texto completo

82. Shitara K, Shah MA, Lordick F, et al. Zolbetuximab in gastric or gastroesophageal junction adenocarcinoma. N Engl J Med. 2024 Sep 26;391(12):1159-62. Resumo

83. Shitara K, Lordick F, Bang YJ, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023 May 20;401(10389):1655-68. Resumo

84. National Institute for Health and Care Excellence. Zolbetuximab with chemotherapy for untreated claudin-18.2-positive HER2-negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma. Mar 2025 [internet publication].Texto completo

85. Cunningham D, Rao S, Starling T, et al. Randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric (OG) cancer: The REAL 2 trial. Abstract LBA4017. Paper presented at: 2006 ASCO Annual Meeting. J Clin Oncol. 2006 Jun 20;24(18 Suppl):LBA4017.

86. Al-Batran S, Hartmann JT, Probst S, et al. A randomized phase III trial in patients with advanced adenocarcinoma of the stomach receiving first-line chemotherapy with fluorouracil, leucovorin and oxaliplatin (FLO) versus fluorouracil, leucovorin and cisplatin (FLP). Abstract LBA4016. Paper presented at: 2006 ASCO Annual Meeting. J Clin Oncol. 2006 Jun 20;24(18 Suppl):LBA4016.

87. Montagnani F, Turrisi G, Marinozzi C, et al. Effectiveness and safety of oxaliplatin compared to cisplatin for advanced, unresectable gastric cancer: a systematic review and meta-analysis. Gastric Cancer. 2011 Mar;14(1):50-5. Resumo

88. National Institute for Health and Care Excellence. Pembrolizumab with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma. Jun 2024 [internet publication].Texto completo

89. National Institute for Health and Care Excellence. Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency. Sep 2023 [internet publication].Texto completo

90. Janmaat VT, Steyerberg EW, van der Gaast A, et al. Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer. Cochrane Database Syst Rev. 2017 Nov 28;11(11):CD004063.Texto completo  Resumo

91. Boku N, Yamamoto S, Fukuda H, et al; Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol. 2009 Nov;10(11):1063-9. Resumo

92. Sasako M, Sakuramoto S, Katai H, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011 Nov 20;29(33):4387-93. Resumo

93. Yoshida K, Kodera Y, Kochi M, et al. Addition of docetaxel to oral fluoropyrimidine improves efficacy in patients with stage III gastric cancer: interim analysis of JACCRO GC-07, a randomized controlled trial. J Clin Oncol. 2019 May 20;37(15):1296-304.Texto completo  Resumo

94. Zhang X, Liang H, Li Z, et al; RESOLVE study group. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. Lancet Oncol. 2021 Aug;22(8):1081-92. Resumo

95. Zhang X, Liang H, Li Z, et al. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): final report of a randomised, open-label, phase 3 trial. Lancet Oncol. 2025 Mar;26(3):312-9. Resumo

96. Wainberg ZA, Kang YK, Lee KW, et al. Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial. Gastric Cancer. 2024 May;27(3):558-70.Texto completo  Resumo

97. ClinicalTrials.gov. Bemarituzumab plus chemotherapy and nivolumab versus chemotherapy and nivolumab for FGFR2b overexpressed untreated advanced gastric and gastroesophageal junction cancer. (FORTITUDE-102). ClinicalTrials.gov Identifier: NCT05111626. Sep 2024 [internet publication].Texto completo

98. ClinicalTrials.gov. Bemarituzumab or placebo plus chemotherapy in gastric cancers with fibroblast growth factor receptor 2b (FGFR2b) overexpression (FORTITUDE-101). ClinicalTrials.gov Identifier: NCT04229004. Jun 2024 [internet publication].Texto completo

99. Pavlakis N, Sjoquist KM, Martin AJ, et al. Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): a multinational placebo-controlled phase II trial. J Clin Oncol. 2016 Aug 10;34(23):2728-35.Texto completo  Resumo

100. Martin AJ, Gibbs E, Sjoquist K, et al. Health-related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma. Gastric Cancer. 2018 May;21(3):473-80.Texto completo  Resumo

101. Lam LL, Pavlakis N, Shitara K, et al. INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG). BMC Cancer. 2023 Feb 22;23(1):180.Texto completo  Resumo

102. Pavlakis N, Shitara K, Sjoquist K, et al. INTEGRATE IIa phase III study: regorafenib for refractory advanced gastric cancer. J Clin Oncol. 2025 Feb;43(4):453-63. Resumo

103. ClinicalTrials.gov. RegoNivo vs standard of care chemotherapy in AGOC (INTEGRATEIIb). ClinicalTrials.gov Identifier: NCT04879368. May 2024 [internet publication].Texto completo

104. Catenacci DV, Rosales M, Chung HC, et al. MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma. Future Oncol. 2021 Apr;17(10):1155-64.Texto completo  Resumo

105. ClinicalTrials.gov. Combination margetuximab, retifanlimab, tebotelimab, and chemotherapy phase 2/3 trial in HER2+ gastric/GEJ Cancer (MAHOGANY). NCT04082364. Apr 2022 [internet publication].Texto completo

106. Lakhani NJ, Chow LQM, Gainor JF, et al. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study. Lancet Oncol. 2021 Dec;22(12):1740-51. Resumo

107. ClinicalTrials.gov. A study of evorpacept (ALX148) in patients with advanced HER2+ gastric cancer (ASPEN-06). NCT05002127. Apr 2022 [internet publication].Texto completo

108. ClinicalTrials.gov. Study of TJ033721 in subjects with advanced or metastatic solid tumors. NCT04900818. Apr 2022 [internet publication].Texto completo

109. Xu J, Jiang H, Pan Y, et al. Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the ORIENT-16 randomized clinical trial. JAMA. 2023 Dec 5;330(21):2064-74.Texto completo  Resumo

110. Zhang X, Wang J, Wang G, et al. First-line sugemalimab plus chemotherapy for advanced gastric cancer: the GEMSTONE-303 randomized clinical trial. JAMA. 2025 Apr 15;333(15):1305-14.Texto completo  Resumo

111. National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program. Cancer stat facts: stomach cancer. 2025 [internet publication].Texto completo

112. Yao JC, Crane CC, Mansfield PF. Carcinoma of the stomach. In: Kufe DW, Bast R, Hait W, et al, eds. Cancer medicine. 7th ed. Hamilton, Ontario: BC Decker; 2006:1268-91.

113. Kasakura Y, Ajani JA, Mochizuki F, et al. Outcomes after emergency surgery for gastric perforation or severe bleeding in patients with gastric cancer. J Surg Oncol. 2002 Aug;80(4):181-5. Resumo

114. LeBoff MS, Greenspan SL, Insogna KL, et al. The clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int. 2022 Oct;33(10):2049-102. Resumo

115. Emery J, Butow P, Lai-Kwon J, et al. Management of common clinical problems experienced by survivors of cancer. Lancet. 2022 Apr 16;399(10334):1537-50. Resumo

116. Roeland EJ, Bohlke K, Baracos VE, et al. Management of cancer cachexia: ASCO guideline. J Clin Oncol. 2020 Jul 20;38(21):2438-53.Texto completo  Resumo

117. Roeland EJ, Bohlke K, Baracos VE, et al. Cancer cachexia: ASCO guideline rapid recommendation update. J Clin Oncol. 2023 Sep 1;41(25):4178-9.Texto completo  Resumo

118. Sandhya L, Devi Sreenivasan N, Goenka L, et al. Randomized double-blind placebo-controlled study of olanzapine for chemotherapy-related anorexia in patients with locally advanced or metastatic gastric, hepatopancreaticobiliary, and lung cancer. J Clin Oncol. 2023 May 10;41(14):2617-27.Texto completo  Resumo

119. Zhou X, Yao Z, Bai H, et al. Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis. Lancet Oncol. 2021 Sep;22(9):1265-74. Resumo

120. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: management of immune checkpoint inhibitor-related toxicities [internet publication].Texto completo

121. Haanen J, Obeid M, Spain L, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022 Dec;33(12):1217-38.

122. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006 Nov 1;24(31):4991-7. Resumo

123. Waters JS, Norman A, Cunningham D, et al. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer. 1999 Apr;80(1-2):269-72. Resumo